OBJECTIVE: We investigated whether a reduced iso-α acid derived from an extract of Humulus lupulus L., META060, had an effect on weight gain, body composition, and metabolism in a high-fat-diet (HFD) fed mouse model. METHODS: Weight gain was monitored for up to 20 wk in mice receiving a low-fat diet, an HFD, or an HFD supplemented with META060 or rosiglitazone. Body composition was determined using dual-energy x-ray absorptiometric analysis. Indirect calorimetric measurements were performed to investigate the energy balance in the mice, and oral glucose tolerance tests were administered to examine the effect of META060 on the glycemic response. RESULTS: The HFD-fed mice administered META060 for 14 wk had a significantly lower mean weight than HFD-fed mice (30.58 ± 0.5 versus 37.88 ± 0.7 g, P < 0.05). Indirect calorimetric measurements showed an increased metabolic flexibility in mice supplemented with META060. In addition, glucose tolerance was improved, comparable to the effects of rosiglitazone treatment. CONCLUSIONS: META060 has potential therapeutic value for managing obesity and insulin resistance, and further research into the mechanism of action is warranted.
OBJECTIVE: We investigated whether a reduced iso-α acid derived from an extract of Humulus lupulus L., META060, had an effect on weight gain, body composition, and metabolism in a high-fat-diet (HFD) fed mouse model. METHODS:Weight gain was monitored for up to 20 wk in mice receiving a low-fat diet, an HFD, or an HFD supplemented with META060 or rosiglitazone. Body composition was determined using dual-energy x-ray absorptiometric analysis. Indirect calorimetric measurements were performed to investigate the energy balance in the mice, and oral glucose tolerance tests were administered to examine the effect of META060 on the glycemic response. RESULTS: The HFD-fed mice administered META060 for 14 wk had a significantly lower mean weight than HFD-fed mice (30.58 ± 0.5 versus 37.88 ± 0.7 g, P < 0.05). Indirect calorimetric measurements showed an increased metabolic flexibility in mice supplemented with META060. In addition, glucose tolerance was improved, comparable to the effects of rosiglitazone treatment. CONCLUSIONS: META060 has potential therapeutic value for managing obesity and insulin resistance, and further research into the mechanism of action is warranted.
Authors: Bernard P Kok; Andrea Galmozzi; Nicole K Littlejohn; Verena Albert; Cristina Godio; Woojoo Kim; Sean M Kim; Jeffrey S Bland; Neile Grayson; Mingliang Fang; Wolfgang Meyerhof; Gary Siuzdak; Supriya Srinivasan; Maik Behrens; Enrique Saez Journal: Mol Metab Date: 2018-08-04 Impact factor: 7.422
Authors: Reem T Atawia; Haroldo A Toque; Mohamed M Meghil; Tyler W Benson; Nicole K H Yiew; Christopher W Cutler; Neal L Weintraub; Ruth B Caldwell; Robert W Caldwell Journal: Int J Mol Sci Date: 2019-03-22 Impact factor: 5.923
Authors: Philip A Kern; Brian S Finlin; Dorothy Ross; Tania Boyechko; Beibei Zhu; Neile Grayson; Robert Sims; Jeffrey S Bland Journal: J Endocr Soc Date: 2017-04-21
Authors: Sam Virtue; Kasparas Petkevicius; José Maria Moreno-Navarrete; Benjamin Jenkins; Daniel Hart; Martin Dale; Albert Koulman; José Manuel Fernández-Real; Antonio Vidal-Puig Journal: Cell Rep Date: 2018-08-21 Impact factor: 9.423